AB0737 MEASUREMENT PROPERTIES OF RADIOGRAPHIC OUTCOME MEASURES IN PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW FROM THE GRAPPA-OMERACT INITIATIVE
Authors: A. Antony, R. Holland, W. Mokkink, M. A. D’agostino, W. P. Maksymowych, H. Bertheussen, L. Schick, N. Goel, A. Ogdie, A. M. Orbai, P. Hoejgaard, L. C. Coates, V. Strand, D. D. Gladman, R. Christensen, Y. Y. Leung, P. J. Mease, W. Tillett
Journal: Annals of the Rheumatic Diseases (2020)

Background: Structural damage was identified as an important outcome domain in the Psoriatic Arthritis (PsA) Core Domain Set and should be assessed at least once in the development of a new therapeutic. Objectives: To conduct a systematic literature review (SLR) to identify studies addressing the measurement properties (MPs) for ROIs and appraise the evidence through the OMERACT Filter 2.1 Framework Instrument Selection Algorithm (OFISA). [1] Methods: An SLR was conducted in EMBASE and MEDLINE to identify full-text English studies developing or assessing MPs of ROIs in PsA. Determination of eligibility, data extraction and methodology asssessment were performed by 2 reviewers. MPs were rated according to the ‘Provisional Standards’ and assigned a Red/Amber/White/Green (RAWG) rating (Figure 1). [1, 2] Results: 3621 references were screened, 531 full-text articles reviewed, and 12 were included (Figure 2). Nine instruments assessing peripheral radiographs and six assessing axial radiographs were identified (Table 1). Three of the nine peripheral radiographic instruments had adequate evidence for reliability and some evidence for construct validity: the modified Steinbrocker, Ratingen, and modified Sharp van der Heijde scores. There was scant evidence for reliability, construct validity and responsiveness for the axial ROIs, compounded by the lack of a standardized definition of axial PsA. Conclusion: This SLR summarizes the MPs of ROIs and identifies relevant knowledge gaps that need to be addressed prior to endorsement of an instrument for the PsA Core Domain Set. References: [1]Richards P and De Wit M, editors. The OMERACT Handbook (March 2019) [2]Mokkink LB and D’Agostino MA. Protocol for performing a systematic review on imaging techniques (unpublished) Figure 1. Criteria for the RAWG Rating Figure 2. PRISMA Diagram Table 1. Summary of Measurement Properties ROI Domain Match Feasibility Construct Validity Discrimination Reliability Responsiveness Inter-rater Intra-rater Measurement Error Longitudinal Construct Validity Clinical Trial Discrimination Thresholds of Meaning Original Steinbrocker Score A [1] A [1] R [1] Modified Steinbrocker Score # G [2] G [2] A [1] A [2] Modified Larsen Score A [1] A [1] A [1] * Ratingen Score # A [1] G [3] G [3] A [3] A [1] mTSS-A A [1] A [1] A [1] mTSS-B # A [1] A [1] A [1] A [1] * mSvdHs # A [2] G [2] G [2] A [1] A [1] * ReXPsA R [0] SPARS # A [1] A [1] A [1] Axial PsA Definition 1 MSASSS # A [2] R [0] BASRI - Total # A [2] R [0] PASRI # A [2] R [0] Axial PsA Definition 2 MSASSS # A [1] R [1] A [1] A [1] BASRI - Spine # R [1] A [1] A [1] PASRI # A [1] A [1] A [1] Modified NYC # R [1] A [1] RASSS # R [1] A [1] A [1] A = Amber, R = Red, G = Green [Total available studies for synthesis following excluding studies with poor methodology] * RCT data available but no published effect sizes # Feasibility data available Disclosure of Interests: Anna Antony: None declared, Richard Holland: None declared, Wieneke Mokkink: None declared, Maria-Antonietta d’Agostino: None declared, Walter P Maksymowych Grant/research support from: Received research and/or educational grants from Abbvie, Novartis, Pfizer, UCB, Consultant of: WPM is Chief Medical Officer of CARE Arthritis Limited, has received consultant/participated in advisory boards for Abbvie, Boehringer, Celgene, Eli-Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, UCB, Speakers bureau: Received speaker fees from Abbvie, Janssen, Novartis, Pfizer, UCB., Heidi Bertheussen: None declared, Lori Schick: None declared, Niti Goel Shareholder of: UCB and Galapagos, Consultant of: VielaBio, Mallinckrodt, and IMMVention, Alexis Ogdie Grant/research support from: Pfizer, Novartis, Consultant of: Abbvie, Amgen, BMS, Celgene, Corrona, Janssen, Lilly, Pfizer, Novartis, Ana-Maria Orbai Grant/research support from: Abbvie, Eli Lilly and Company, Celgene, Novartis, Janssen, Horizon, Consultant of: Eli Lilly; Janssen; Novartis; Pfizer; UCB. Ana-Maria Orbai was a private consultant or advisor for Sun Pharmaceutical Industries, Inc, not in her capacity as a Johns Hopkins faculty member and was not compensated for this service., Pil Hoejgaard: None declared, Laura C Coates: None declared, Vibeke Strand Consultant of: AbbVie, Amgen, Biogen, Celltrion, Consortium of Rheumatology Researchers of North America, Crescendo Bioscience, Eli Lilly, Genentech/Roche, GlaxoSmithKline, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, UCB, Dafna D Gladman Grant/research support from: AbbVie, Amgen Inc., BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB – grant/research support, Consultant of: AbbVie, Amgen Inc., BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB – consultant, Robin Christensen: None declared, Ying Ying Leung Speakers bureau: Novartis, Janssen, Eli Lilly, Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau, William Tillett Grant/research support from: AbbVie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, UCB, Consultant of: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, MSD, Pfizer Inc, UCB, Speakers bureau: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, Pfizer Inc, UCB